O-Phosphoethanolamine (PEA)

O-Phosphoethanolamine (PEA) is a naturally occurring polar head group precursor required for the de novo synthesis of phosphatidylethanolamine (PE) via the Kennedy pathway. It serves as a vital intermediate in phospholipid metabolism, contributing to the structural and functional integrity of cellular and mitochondrial membranes. In clinical diagnostics, elevated urinary levels of phosphoethanolamine are a hallmark biomarker for hypophosphatasia (HPP), a rare genetic disorder characterized by deficient tissue-nonspecific alkaline phosphatase activity and impaired bone mineralization. Beyond its role as a metabolite, 'synthetic phosphoethanolamine' has been investigated as a controversial experimental anticancer agent. In oncology research, it is proposed to induce apoptosis in malignant cells by disrupting mitochondrial electron transport and altering lipid signaling pathways. Despite some promising preclinical results, its therapeutic efficacy remains unproven in robust human clinical trials.

Other names

Phosphoethanolamine2-aminoethyl phosphateEthanolamine O-phosphateColamine phosphatePhosphorylethanolamine2-Aminoethyl dihydrogen phosphate

As an experimental anticancer agent, phosphoethanolamine is proposed to alter mitochondrial membrane potential, inhibit the electron transport chain (specifically oxidative phosphorylation), and induce selective apoptosis in tumor cells. In the context of metabolic disease, it is a substrate for the enzyme tissue-nonspecific alkaline phosphatase (ALPL/TNSALP); in the absence of adequate enzyme activity, the molecule accumulates and is excreted as a biomarker.